Quick Answer
Syndax Pharmaceuticals Inc reported Diluted EPS of $3.29 per share (loss) for fiscal year 2025.
Syndax Pharmaceuticals Inc Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.29 | +11.6% |
| 2024 | -$3.72 | -24.8% |
| 2023 | -$2.98 | -21.1% |
| 2022 | -$2.46 | -634.8% |
| 2021 | $0.46 | +124.6% |
| 2020 | -$1.87 | -1.6% |
| 2019 | -$1.84 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.70 | +28.6% | +15.7% |
| June 30, 2025 | -$0.83 | -3.7% | +15.3% |
| March 31, 2025 | -$0.98 | -15.3% | +0.0% |
| September 30, 2024 | -$0.98 | -34.2% | -22.5% |
| June 30, 2024 | -$0.80 | -25.0% | +5.9% |
| March 31, 2024 | -$0.85 | -44.1% | -16.4% |
| September 30, 2023 | -$0.73 | -25.9% | -14.1% |
| June 30, 2023 | -$0.64 | -3.2% | -8.5% |
- Syndax Pharmaceuticals Inc showed an increase of +11.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Syndax Pharmaceuticals Inc’s diluted eps has declined by 78.8% (from $1.84 per share (loss) to $3.29 per share (loss)).
- The most recent figure is from Syndax Pharmaceuticals Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: